{"id":30544,"date":"2022-04-29T07:55:04","date_gmt":"2022-04-29T13:55:04","guid":{"rendered":"https:\/\/brakkeconsulting.com\/?p=30544"},"modified":"2022-04-29T07:55:50","modified_gmt":"2022-04-29T13:55:50","slug":"brakke-viewpoint-april-29-2022","status":"publish","type":"post","link":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-april-29-2022\/","title":{"rendered":"Ponto de vista de Brakke 29 de abril de 2022"},"content":{"rendered":"

Um relat\u00f3rio recente do Instituto IQVIA intitulado \u201cO uso de medicamentos nos EUA 2022<\/a>\u201d \u00e9 uma leitura interessante se voc\u00ea acredita que as tend\u00eancias da medicina humana eventualmente aparecem na medicina veterin\u00e1ria. Alguns resultados not\u00e1veis\u2026<\/p>\n

Primeiro, o uso geral de telessa\u00fade voltou aos n\u00edveis pr\u00e9-pand\u00eamicos no final de 2021, ou 1-2% de visitas de pacientes. A sa\u00fade mental teve aumentos dram\u00e1ticos na telessa\u00fade durante a pandemia, atingindo um pico de cerca de 30% de todas as visitas e agora \u00e9 de cerca de 20%. As consultas de telessa\u00fade para doen\u00e7as cr\u00f4nicas, como hipertens\u00e3o, diabetes e HIV\/AIDS, atingiram um pico entre 5 a 11% de visitas, mas agora ca\u00edram para 1-2%, porque essas doen\u00e7as frequentemente exigem testes e exames de sangue.<\/p>\n

Em segundo lugar, os gastos com medicamentos especiais nos EUA representam 55% da receita l\u00edquida total do fabricante. Esses medicamentos tratam doen\u00e7as autoimunes, oncologia e esclerose m\u00faltipla e agora s\u00e3o quase o dobro do n\u00edvel de 2011, que era 28%.<\/p>\n

Finalmente, todo o crescimento dos gastos com medicamentos nos \u00faltimos 5 anos ($82.0B) deveu-se a novos produtos ($87.7B). O impacto do volume de produtos patenteados j\u00e1 lan\u00e7ados (+$94B) foi totalmente compensado por produtos fora de patente (-$93.0B).<\/p>\n

A medicina veterin\u00e1ria geralmente segue os passos da sa\u00fade humana, ent\u00e3o o que podemos aprender com este relat\u00f3rio? A inova\u00e7\u00e3o focada em produtos especiais provavelmente impulsionar\u00e1 o crescimento futuro da medicina veterin\u00e1ria, enquanto a inova\u00e7\u00e3o em servi\u00e7os, como a telessa\u00fade, ser\u00e1 mais dif\u00edcil de vender.<\/p>\n

Bob Jones<\/em><\/p>","protected":false},"excerpt":{"rendered":"

Um relat\u00f3rio recente do Instituto IQVIA intitulado \u201cO Uso de Medicamentos nos EUA 2022\u201d \u00e9 uma leitura interessante se voc\u00ea acredita que as tend\u00eancias na medicina humana eventualmente aparecem na medicina veterin\u00e1ria. Alguns resultados not\u00e1veis\u2026 Em primeiro lugar, a utiliza\u00e7\u00e3o global da telessa\u00fade regressou aos n\u00edveis pr\u00e9-pand\u00e9micos no final de 2021, ou 1-2% de consultas de pacientes. A sa\u00fade mental registou aumentos dram\u00e1ticos na telessa\u00fade durante a pandemia, atingindo um pico de cerca de 30% de todas as visitas, e agora \u00e9 de cerca de 20%. As consultas de telessa\u00fade para doen\u00e7as cr\u00f3nicas, como hipertens\u00e3o, diabetes e VIH\/SIDA, atingiram um pico entre 5 e 11% de consultas, mas ca\u00edram agora para 1-2%, porque estas doen\u00e7as requerem frequentemente testes e an\u00e1lises ao sangue. Em segundo lugar, os gastos com medicamentos especializados nos EUA representam 55% da receita l\u00edquida total do fabricante. Esses medicamentos tratam doen\u00e7as autoimunes, oncologia e esclerose m\u00faltipla e agora representam cerca do dobro do n\u00edvel de 2011, que era 28%. Finalmente, todo o crescimento nos gastos com medicamentos nos \u00faltimos 5 anos ($82.0B) deveu-se a novos produtos ($87.7B). O impacto de volume dos produtos patenteados j\u00e1 lan\u00e7ados (+$94B) foi completamente compensado pelos produtos que deixaram de ser patenteados (-$93,0B). A medicina veterin\u00e1ria segue frequentemente os passos da sa\u00fade humana, ent\u00e3o o que podemos aprender com este relat\u00f3rio? A inova\u00e7\u00e3o centrada em produtos especializados dever\u00e1 impulsionar o crescimento futuro da medicina veterin\u00e1ria, enquanto a inova\u00e7\u00e3o em servi\u00e7os, como<\/p>\n

Ver postagem completa<\/a><\/div>\n

;<\/p>","protected":false},"author":19,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[43],"tags":[],"class_list":["post-30544","post","type-post","status-publish","format-standard","hentry","category-viewpoints"],"acf":[],"yoast_head":"\nNews from Brakke Consulting<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-april-29-2022\/\" \/>\n<meta property=\"og:locale\" content=\"pt_PT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"News from Brakke Consulting\" \/>\n<meta property=\"og:description\" content=\"A recent report from the IQVIA Institute entitled \u201cThe Use of Medicines in the US 2022\u201d is interesting reading if you believe that trends in human medicine eventually show up in veterinary medicine.\u00a0 Some notable results\u2026 First, the overall use of telehealth has returned to pre-pandemic levels at the end of 2021, or 1-2% of patient visits.\u00a0 Mental health saw dramatic increases in telehealth during the pandemic, peaking at about 30% of all visits, and is now about 20%.\u00a0 Telehealth visits for chronic diseases, like hypertension, diabetes, and HIV\/AIDS, peaked between 5 to 11% of visits, but are now down to 1-2%, because these diseases frequently require testing and bloodwork. Second, spending on specialty medicines in the US is 55% of total net manufacturer revenue.\u00a0 These medicines treat autoimmune diseases, oncology, and multiple sclerosis and is now about double the 2011 level, which was 28%. Finally, all the growth in medicine spending in the past 5 years, ($82.0B) has been due to new products ($87.7B).\u00a0 The volume impact of patented products already launched (+$94B) was completely offset by products going off patent (-$93.0B). Veterinary medicine often follows in the footsteps of human health, so what can we learn from this report? Innovation focused on specialty products is likely to drive future growth in veterinary medicine, while innovation in services, likeView Full Post;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-april-29-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Brakke Consulting Website\" \/>\n<meta property=\"article:published_time\" content=\"2022-04-29T13:55:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-04-29T13:55:50+00:00\" \/>\n<meta name=\"author\" content=\"Amanda McDavid\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Amanda McDavid\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo estimado de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-april-29-2022\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-april-29-2022\/\"},\"author\":{\"name\":\"Amanda McDavid\",\"@id\":\"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615\"},\"headline\":\"Brakke Viewpoint April 29, 2022\",\"datePublished\":\"2022-04-29T13:55:04+00:00\",\"dateModified\":\"2022-04-29T13:55:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-april-29-2022\/\"},\"wordCount\":223,\"articleSection\":[\"Viewpoints\"],\"inLanguage\":\"pt-PT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-april-29-2022\/\",\"url\":\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-april-29-2022\/\",\"name\":\"News from Brakke Consulting\",\"isPartOf\":{\"@id\":\"https:\/\/brakkeconsulting.com\/#website\"},\"datePublished\":\"2022-04-29T13:55:04+00:00\",\"dateModified\":\"2022-04-29T13:55:50+00:00\",\"author\":{\"@id\":\"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615\"},\"breadcrumb\":{\"@id\":\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-april-29-2022\/#breadcrumb\"},\"inLanguage\":\"pt-PT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-april-29-2022\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-april-29-2022\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/brakkeconsulting.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Brakke Viewpoint April 29, 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/brakkeconsulting.com\/#website\",\"url\":\"https:\/\/brakkeconsulting.com\/\",\"name\":\"Brakke Consulting Website\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/brakkeconsulting.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-PT\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615\",\"name\":\"Amanda McDavid\",\"url\":\"https:\/\/brakkeconsulting.com\/pt\/author\/amanda\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Not\u00edcias da Brakke Consulting","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-april-29-2022\/","og_locale":"pt_PT","og_type":"article","og_title":"News from Brakke Consulting","og_description":"A recent report from the IQVIA Institute entitled \u201cThe Use of Medicines in the US 2022\u201d is interesting reading if you believe that trends in human medicine eventually show up in veterinary medicine.\u00a0 Some notable results\u2026 First, the overall use of telehealth has returned to pre-pandemic levels at the end of 2021, or 1-2% of patient visits.\u00a0 Mental health saw dramatic increases in telehealth during the pandemic, peaking at about 30% of all visits, and is now about 20%.\u00a0 Telehealth visits for chronic diseases, like hypertension, diabetes, and HIV\/AIDS, peaked between 5 to 11% of visits, but are now down to 1-2%, because these diseases frequently require testing and bloodwork. Second, spending on specialty medicines in the US is 55% of total net manufacturer revenue.\u00a0 These medicines treat autoimmune diseases, oncology, and multiple sclerosis and is now about double the 2011 level, which was 28%. Finally, all the growth in medicine spending in the past 5 years, ($82.0B) has been due to new products ($87.7B).\u00a0 The volume impact of patented products already launched (+$94B) was completely offset by products going off patent (-$93.0B). Veterinary medicine often follows in the footsteps of human health, so what can we learn from this report? Innovation focused on specialty products is likely to drive future growth in veterinary medicine, while innovation in services, likeView Full Post;","og_url":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-april-29-2022\/","og_site_name":"Brakke Consulting Website","article_published_time":"2022-04-29T13:55:04+00:00","article_modified_time":"2022-04-29T13:55:50+00:00","author":"Amanda McDavid","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Amanda McDavid","Tempo estimado de leitura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-april-29-2022\/#article","isPartOf":{"@id":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-april-29-2022\/"},"author":{"name":"Amanda McDavid","@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615"},"headline":"Brakke Viewpoint April 29, 2022","datePublished":"2022-04-29T13:55:04+00:00","dateModified":"2022-04-29T13:55:50+00:00","mainEntityOfPage":{"@id":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-april-29-2022\/"},"wordCount":223,"articleSection":["Viewpoints"],"inLanguage":"pt-PT"},{"@type":"WebPage","@id":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-april-29-2022\/","url":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-april-29-2022\/","name":"Not\u00edcias da Brakke Consulting","isPartOf":{"@id":"https:\/\/brakkeconsulting.com\/#website"},"datePublished":"2022-04-29T13:55:04+00:00","dateModified":"2022-04-29T13:55:50+00:00","author":{"@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615"},"breadcrumb":{"@id":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-april-29-2022\/#breadcrumb"},"inLanguage":"pt-PT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-april-29-2022\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-april-29-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/brakkeconsulting.com\/"},{"@type":"ListItem","position":2,"name":"Brakke Viewpoint April 29, 2022"}]},{"@type":"WebSite","@id":"https:\/\/brakkeconsulting.com\/#website","url":"https:\/\/brakkeconsulting.com\/","name":"Site da Brakke Consulting","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/brakkeconsulting.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-PT"},{"@type":"Person","@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615","name":"Amanda McDavid","url":"https:\/\/brakkeconsulting.com\/pt\/author\/amanda\/"}]}},"_links":{"self":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/30544","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/users\/19"}],"replies":[{"embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/comments?post=30544"}],"version-history":[{"count":1,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/30544\/revisions"}],"predecessor-version":[{"id":30545,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/30544\/revisions\/30545"}],"wp:attachment":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/media?parent=30544"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/categories?post=30544"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/tags?post=30544"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}